GSK’s Zejula Wins First-Line Ovarian Cancer Use

FDA Extension Is PARP Inhibitor’s Third Indication In That Disease

 
• By Sten Stovall
Niraparib_Molecule
Oral, once-daily PARP inhibitor niraparib is being evaluated in multiple pivotal trials. • Source: Shutterstock

More from Clinical Trials

More from R&D